» Articles » PMID: 21652007

Mortality in Friedreich Ataxia

Overview
Journal J Neurol Sci
Publisher Elsevier
Specialty Neurology
Date 2011 Jun 10
PMID 21652007
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although cardiac dysfunction is widely accepted as the most common cause of mortality in Friedreich ataxia (FRDA), no studies have evaluated this since the advent of specific clinical and genetic diagnostic criteria.

Methods: We performed a retrospective study of FRDA patients to determine cause of death followed by a case-control analysis comparing characteristics of deceased patients with living, age- and sex-matched FRDA controls.

Results: Causes of death were cardiac dysfunction (59%), probable cardiac dysfunction (3.3%), non-cardiac (27.9%) or unknown (9.8%). Compared to non-cardiac deaths, cardiac deaths occurred earlier in the disease course (median 29 vs. 17years respectively). Congestive heart failure and arrhythmia were common causes of cardiac-related death. Compared to living, matched FRDA controls, deceased patients had longer triplet repeat lengths and higher rates of arrhythmia and dilated cardiomyopathy. The presence of hypertrophic cardiomyopathy did not differ between deceased and living patients.

Conclusion: Cardiac dysfunction was the most frequent cause of death (59%), most commonly from congestive heart failure or arrhythmia. Arrhythmia and dilated cardiomyopathy were significantly more common in deceased patients compared to matched FRDA controls, while in contrast, the presence of cardiac hypertrophy did not differ. More research is needed to establish the clinical significance of hypertrophy in FRDA.

Citing Articles

A global perspective on research advances and future challenges in Friedreich ataxia.

Indelicato E, Delatycki M, Farmer J, Franca Jr M, Perlman S, Rai M Nat Rev Neurol. 2025; .

PMID: 40032987 DOI: 10.1038/s41582-025-01065-y.


Friedreich Ataxia: An (Almost) 30-Year History After Gene Discovery.

Pandolfo M Neurol Genet. 2025; 11(1):e200236.

PMID: 39810753 PMC: 11731367. DOI: 10.1212/NXG.0000000000200236.


Safety and efficacy of omaveloxolone v/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16 years: a systematic review.

Umrao A, Pahuja M, Chatterjee N Orphanet J Rare Dis. 2024; 19(1):495.

PMID: 39736600 PMC: 11684145. DOI: 10.1186/s13023-024-03474-6.


Triplex H-DNA structure: the long and winding road from the discovery to its role in human disease.

Hisey J, Masnovo C, Mirkin S NAR Mol Med. 2024; 1(4):ugae024.

PMID: 39723156 PMC: 11667243. DOI: 10.1093/narmme/ugae024.


Precision medicine and Friedreich ataxia: promoting equity, beneficence, and informed consent for novel gene therapies.

Kwa F, Kendal E Int J Equity Health. 2024; 23(1):230.

PMID: 39516866 PMC: 11545357. DOI: 10.1186/s12939-024-02318-w.